Armata Pharmaceuticals Inc(ARMP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -7.59 | Insider Own | 67.99% | Shs Outstand | 37.1M | Perf Week | 11.65% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | 22.52% | Insider Trans | - | Shs Float | 11.9M | Perf Month | -5.22% |
| Enterprise Value | 0.42B | PEG | - | EPS next Q | -0.56 | Inst Own | 13.43% | Short Float | 8.1% | Perf Quarter | -25.97% |
| Income | -0.19B | P/S | 23.16 | EPS this Y | 61.15% | Inst Trans | 3.1% | Short Ratio | 5.12 | Perf Half Y | -74.5% |
| Sales | 0.01B | P/B | - | EPS next 5Y | 38.99% | ROA | -225.11% | Short Interest | 0.96M | Perf YTD | -45.06% |
| Book/sh | -6.22 | P/C | 5.36 | EPS past 3/5Y | -64.55% -28.83% | ROE | - | 52W High | -78.89% ($16.34) | Perf Year | -51.06% |
| Cash/sh | 0.64 | P/FCF | - | Sales past 3/5Y | -3.8% 42.9% | ROIC | - | 52W Low | 25.68% ($2.74) | Perf 3Y | 74.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -645.64% | Gross Margin | 66.88% | Volatility(W/M) | 12.07% 10.07% | Perf 5Y | 14.24% |
| Dividend TTM | - | EV/Sales | 75.5 | Sales Y/Y TTM | -19.29% | Oper. Margin | -636.55% | ATR (14) | 0.4 | Perf 10Y | -98.07% |
| Dividend Ex-Date | - | Quick Ratio | 0.11 | EPS Q/Q | 39.58% | Profit Margin | -3467.04% | RSI (14) | 46.07 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.11 | Sales Q/Q | 15.72% | SMA20 | -0.25% ($3.46) | Beta | 1.53 | Target Price | $17.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/12 | SMA50 | -20.4% ($4.33) | Rel Volume | 0.57 | Prev Close | $3.06 |
| Employees | 61 | LT Debt/Eq | - | EPS/Sales Surpr. | 39.33% 527.5% | SMA200 | -51.5% ($7.11) | Avg Volume(3M) | 0.19M | Price | $3.45 |
| IPO | 1994/5/20 | Option/Short | Yes/Yes | Trades | 748 | Volume | 108,004 | Change | 12.75% |
Armata Pharmaceuticals, ticker ARMP, is a clinical-stage biotech company that uses bacteriophages (viruses that infect bacteria) to treat antibiotic-resistant bacterial infections. Centered on its lead candidates AP-SA02 and AP-PA02, the company targets the unmet medical need of multidrug-resistant bacterial infections and is building a next-generation anti-infective platform with support from Innoviva and the U.S. Department of Defense.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded less than usual. That is 57% of its average volume.
ARMP has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +61.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,316. Peers typically go for $1,138.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +14.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #338 of 594 in the industry
Based on market cap of $128M.
MENS#335 Jyong Biotech Ltd $129M PER - 
RTSN#336 Retension Pharmaceuticals Inc $129M PER - 
TLSA#337 Tiziana Life Sciences Ltd $128M PER - ARMP#338 Armata Pharmaceuticals Inc $128M PER - 
HURA#339 TuHURA Biosciences Inc $128M PER - 
FAQ
What kind of company is ARMP?
ARMP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARMP?
The market cap of ARMP is approximately $128M, ranking 4,333 within its sector.
What is the 52-week high and low for ARMP?
ARMP has recorded a 52-week high of $16.34 and a low of $2.74.
